New study finds effective malaria treatment
A new study published in The Lancet suggests that the combination of artemether and lumefantrine is the most effective available treatment for malaria in children in areas of Africa where resistance to conventional anti-malarial drugs is high.
bdnews24.com News Service
bdnews24.com
Published :
06 May 2005, 06:00 PM
Updated :
17 Aug 2022, 08:36 PM
Dhaka, May 7 (BDNEWS) - A new study published in The Lancet suggests that the combination of artemether and lumefantrine is the most effective available treatment for malaria in children in areas of Africa where resistance to conventional anti-malarial drugs is high.
Developed and produced by Novartis under the brand name Coartem, the medicine is a fixed-dose artemisinin-based combination therapy pre-qualified by the World Health Organization (WHO) for procurement by United Nations agencies.
Recently, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria approved a grant of USD 170 million to seven African nations for the procurement of Coartem over the next two years.
"These new clinical data confirm that Coartem is the current gold standard to treat malaria in areas of high resistance to conventional anti-malarials and is as such a life-saving drug," said Dr. Daniel Vasella, Chairman and CEO of Novartis.
BDNEWS/1353 hrs